

The Journey Towards Confidence --

Bottom-Up PBK Modelling for Benzophenone 4

Hequn Li
(Science Leader at Safety and Environmental
Assurance Centre, Unilever)



Unilever




Making safety decisions without generating data in animals



- Regulations ban animal testing of cosmetic products and their ingredients in over 40 countries
- Many of our consumers do not want to buy products associated with animal testing

At Unilever, our products must be safe

From traditional risk assessment to next generation risk assessment



Benzophenone-4 (BP-4) case study: Objectives & Approach

- **BP-4 is an UV-filter ingredient used in sunscreen cosmetics** to prevent sunburns or photodegradation by inhibiting the infiltration of UV light.
- **Background and Objective of the case study on BP-4:**
 - Work with Cosmetic Europe Long Range Science Strategy (LRSS) on developing new approaches for safety assessment without using animals
 - Unilever led a few case studies within the LRSS, including BP4
 - Objective: to assess whether a tiered NGRA approach is sufficiently protective for making safety decisions

Focus of this presentation

PBK model development of BP-4 based on NAMs to make estimates of systemic exposure levels in NGRA

PBK modelling platform: GastroPlus v9.8


PBK Modelling Workflow and reporting template: compliant with OECD 2021 and WHO guidance



Exposure assessment: From topically applied dose to internal concentrations (e.g. C_{max} , AUC)

External dose


- Route of exposure
- Consumer use (Habits & Practices)
- Applied dose (external concentration)
- Duration and frequency



ADME parameters



Absorption
Distribution
Metabolism
Elimination

- Skin penetration
- Phys-chem properties
- Hepatic clearance
- Fraction unbound
- Blood:plasma ratio



Kinetic profile of chemical

Physiologically-based kinetic (PBK) modelling
– Internal concentration (plasma, urine, organ-level)



Images from: AFSA training module "Dosimetry (Internal Exposure)", 2022

External applied dose

- 5% BP-4 in Sunscreen product
- 18g/day, two times, 9g/application, on body and face 17500cm² (Based on SCCS NoG)
- To closely simulate the real-life use scenarios, it was assumed that European individuals
 - use this sunscreen body lotion in the daytime
 - each day apply the first dose (9g) at 9 am and the second dose (9g) at 2 pm
 - following a meal (fed condition) and take a shower each morning at 7 am

	Dosage Form	Dose [mg]	TD Dose Vol [ml]	Start [h]	End [h]	Physiology or .cat file	PBPK Physiology or .pbk file
	TD: Liq Soln	450	9	0	22	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	5	22	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	24	46	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	29	46	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	48	70	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	53	70	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	72	94	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	77	94	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	96	118	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	101	118	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	120	142	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	125	142	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	144	166	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	149	166	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	168	190	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	173	190	Human - Physiological - Fed	european individual
	TD: Liq Soln	450	9	192	214	Human - Physiological - Fed	european individual

Mixed Multiple Doses (MMD) in GastroPlus to reflect multiple doses of specific amounts at varying intervals.

PhysChem and ADME data generation and parameterisation




Strategy:

- We took a stepwise approach to data generation and refinement,
- using relevant and robust approaches for parameter determination
- support the reliability of input parameters and provide a sound biological basis for the model structure

	Value	Source
Molecular weight	308.3 g/mol	
Log P	1.28	ADMET predictor
pKa	acid 8.89, acid 0.5	ADMET predictor
Fraction unbound in plasma (f_{up})	0.0157	Measured
Blood: plasma ratio	0.6	Measured
Renal excretion	0.11L/h	GFR*Fup

Dermal absorption with *ex vivo* skin pen data

- *Ex vivo* skin penetration study designed according to *Davis et al. 2011* meeting OECD and SCCS guidance
- BP-4 in relevant formulation (oil in water emulsion)
- Full time course data in skin layers and kinetic in receptor fluid



Results

- Very low skin penetration, therefore big variance of the data
- data used to fit important skin penetration parameters, i.e. diffusivity and partitioning parameters, in the TCAT module of GastroPlus

**Receptor fluid:
Below the Limit of Quantification**

Hepatic clearance




In silico:

BP-4 was predicted to be mainly cleared via liver metabolism

In vitro data:

Primary human hepatocyte assay (using both suspension and plated cells):

Hepatic intrinsic clearance <2.5L/h (Below LOQ)



Initial ECCS (Extended Clearance Classification System):


Class 1A

(Varma et al., 2015)

No metabolism of BP-4 seen in hepatocytes, conflicting with the ECCS Class 1A prediction.

Two hypotheses:

- 1) BP-4 is not a substrate of hepatic enzymes
- 2) BP-4 has low membrane permeability



If BP-4 is not metabolised by the liver – what is the route of elimination?
How is BP-4 taken up by the cells?

Back to problem formulation...

Understanding chemical organ distribution and renal clearance

In silico predictions:

- BP-4 is an anion sulphonate
- Likely to be a substrate of Organic anion transporters (OATs)
- Renal clearance may be higher than $GFR \cdot F_{up}$

In vitro 1:

Transporter studies in transfected kidney cells in two different formats

Results:

- Substrate of certain influx transporters and efflux transporters
- All these transporters are expressed in the kidney, related to either active secretion or reabsorption
- OAT-2, BCRP and MRP4 are expressed both in the liver

Transporters	Uptake of efflux?	Substrate?
OAT1	Uptake	Yes
OAT2	Uptake	Yes
OAT3	Uptake	Yes
OCT2	Uptake	No
MATE1	Efflux	No
MATE2-K	Efflux	No
MRP2	Efflux	No
MRP4	Efflux	Yes
MDR1/Pg-p	Efflux	No
BCRP	Efflux	Yes
OAT4	Uptake	YES
OATP1A2	Uptake	Borderline*
OCTN1	Uptake	NO
OCTN2	Uptake	NO
URAT1	Uptake	NO

Back to problem formulation...

Understanding chemical organ distribution and renal clearance

In silico predictions:


- BP-4 is an anion sulphonate
- Likely to be a substrate of Organic anion transporters (OATs)
- Renal clearance may be higher than $GFR \cdot F_{up}$

In vitro 1:

Transporter studies in transfected kidney cells in two different assays (uptake assay and vesicular assay)

In vitro 2:

Investigate the bi-directional transport profile in kidney where all the active transporters are present and functional (aProximate™).



B-A → blood to urine → active secretion
A-B → urine to blood → reabsorption

Human aProximate™ platform


- Primary proximal tubule cells (PTCs) derived from fresh human kidneys
- Cultured on semi-permeable filters to form a tight monolayer
- Retains **a high degree of differentiation**
- Endogenously **express a variety of functional proteins and biomarkers**

Results:

- Route of elimination in the kidney includes glomerular filtration, active tubular secretion and tubular reabsorption
- Transport in the proximal tubule cells is equally efficient in both directions
- However, donor variability has been observed that in 1 donor, active secretion was shown to be the main excretion route at biologically relevant concentrations

Updated PBK model in GastroPlus

- Set BP-4's distribution to each compartment to be modelled as permeability-limited
- Liver clearance set to 0
- Active transport in the liver was modelled by incorporating kinetic parameters (V_{max} , K_m , Protein expression) for the transporters (OAT-2, BCRP and MRP4).
- Biliary excretion not accounted for to be conservative
- $GFR \cdot F_{up}$ was used to calculate renal excretion of BP-4, accounting for filtration only to be conservative




Human PBK model structure for BP-4

PBK modelling

for a female European
30 years-old 60 kg bodyweight

BP4-Systemic Exposure-repeat



PK parameter	Value
Bioavailability (%)	0.4
CL _{renal} (L/h)	0.11
Plasma C _{max} (µM)	2.08
AUC _{24h} (ug-h/mL)	1.94
Volumes of distribution at steady state (L)	8.577
t _{1/2} (h)	54.3

Human clinical PK data is not available for model verification


We need to address uncertainty in PBK estimation

The output of the uncertainty and sensitivity analyses

A

		Uncertainty		
		High	Medium	Low
Sensitivity	High		vehicle: water partition coefficient Stratum corneum water partition coefficient Stratum corneum diffusivity Fup	
	Medium		K _m OAT2	
	Low		V _{max} OAT2 Epidermis diffusivity Blood: plasma ratio	

Plasma Cmax



C

		Uncertainty		
		High	Medium	Low
Sensitivity	High		vehicle: water partition coefficient Stratum corneum water partition coefficient Stratum corneum diffusivity	
	Medium		K _m OAT2 V _{max} OAT2 Fup	
	Low		Blood: plasma ratio	

Kidney intracellular Cmax

According to WHO/OECD guidance

Probabilistic PBK modelling to account for population variability and parameter uncertainty

Monte Carlo simulation

Population

Physiological characteristics

- 16-70 years old
- 40-85 kg
- 50% male and 50 % female
- European population

Parameter uncertainty analysis


- Set ranges (distributions) on values of influential parameters based on available information
- For uninfluential parameters, default distributions used

Note: a limitation of this approach is that parameter uncertainty and variability are considered together. Although separation of parameter uncertainty and variability is theoretically possible using hierarchical, population-based models, data are typically inadequate to achieve such a level or granularity

Probabilistic PBK modelling + CMED model to account for population, parameter and model uncertainty

To account unknown-unknowns e.g. model uncertainty

- C_{max} Error Distribution (CMED): A complementary approach to characterise PBK prediction uncertainty as published in *Li et al. 2022* and *Middleton et al. 2022*.
- This model seeks to quantify the error distribution of estimates of plasma C_{max} by looking at the difference between PBK predictions of C_{max} and existing measured values in human clinicals for several exposure scenarios.
- This model can be used to estimate the distribution of the possible prediction errors for future chemical and exposure scenario.



Deterministic PBK model for female adult 60 kg	Distribution of C_{max} (probabilistic simulation+CMED) (μM)	
Plasma C_{max} point estimate	Median (95% interval)	95 th percentile
2.1	1.3 (0.11, 15)	9.8



Li H, Reynolds J, Sorrell I, Sheffield D, Pendlington R, Cubberley R, Nicol B. PBK modelling of topical application and characterisation of the uncertainty of C_{max} estimate: A case study approach. *Toxicol Appl Pharmacol.* 2022 May 1;442:115992. doi: 10.1016/j.taap.2022.115992. Epub 2022 Mar 25. PMID: 35346730.

Middleton, A.M., et al., Are Non-animal Systemic Safety Assessments Protective? A Toolbox and Workflow. *Toxicological Sciences*, 2022. 189(1): p. 124-147.

Confidence level

WHO questions for assessing the level of confidence in the BP-4 PBK modeling

Model evaluation aspect	level of confidence (towards the accuracy)	level of confidence (towards the conservatism)
Do the model structure and parameters have a reasonable biological basis ?	High	High
How well does the PBK model reproduce the chemical-specific PK data under various experimental or exposure conditions?	Low	High
How reliable is the PBK model with regard to its predictions of dose metrics relevant to risk assessment ?	High	High

Conclusions

- ✓ The stepwise way of data generation and refinement, using relevant and robust approaches for parameter determination, support the reliability of input parameters and provide a sound biological basis for the model structure.
- ✓ Although human clinical data are not available for validation, the sensitivity and uncertainty analyses and the probabilistic modelling performed provided assurance that the predictions are fit for purpose and provides conservative estimates of human systemic exposure.

Acknowledgments

Matt Dent

Maria Baltazar

Sophie Cable

Nicky Hewitt

Beate Nicol

Joe Reynolds

Richard Cubberley

Sandrine Spriggs

Ruth Pendlington

BP4 Consortium

Cosmetics Europe/LRSS Case study Leaders Team

Pharmacelsus

Eurofins

SOLVO

NewCells